Introduction
Cardiovascular disease (CVD) in pregnancy is the leading cause of maternal morbidity and mortality in the UK, 1 South Africa, 2 and North America. 3 Pregnant women with known CVD or newly diagnosed cardiovascular conditions in pregnancy often require cardiovascular imaging during pregnancy to confirm diagnosis, assess disease severity, stratify risk, prognosticate, plan appropriate management, and assess response to therapy. 4 While numerous imaging modalities are available, diagnostic X-ray and nuclear procedures associated with ionizing radiation emerge as the greatest source of concern for patients and clinicians alike. 4 Largely due to lack of safety data for use of medications and some diagnostic tests in pregnancy, virtually all clinical trials exclude pregnant women and those of childbearing age, despite a drive from the United States Food and Drug Administration to increase responsible inclusion of women in research 5 ; the consequence is that pregnant women with CVD are under-investigated and frequently under-treated. 6 Cardiovascular magnetic resonance (CMR) is a powerful imaging modality, free from ionizing radiation, with high spatial and temporal resolution, performed via excitation of hydrogen protons within a powerful magnetic field. 4 The EuroCMR registry including >27 000 patients concluded that CMR is safely being performed in European clinical practice; with demonstration that in 8.7% of studies a completely new diagnosis was made, and 61.8% of scans had a direct impact on patient management. registries and retrospective cohorts and suggest that magnetic resonance imaging (MRI) does not harm the baby when performed at any stage of the pregnancy. 4, [7] [8] [9] [10] In over 25 years of evaluating obstetric, placental, and foetal outcomes in pregnant women, there has been no evidence of harm from the use of CMR and other forms of MRI up to 3 T in pregnancy. 11, 12 Consequently, the guidance from both the American College of Radiology and the European Society of Cardiology is that while MRI is useful for diagnosing complex CVD in pregnancy, it should be used when other modalities, in particular, ultrasound are insufficient for the diagnosis; and that while limited data on organogenesis are available, MRI in general is probably safe, especially after the first trimester. 12, 13 Less data are available on the use of contrast, but Ray et al. 8 report on increased risk of neonatal death or stillbirth with gadolinium exposure. Rheumatological, inflammatory, or infiltrative skin conditions were more common in first trimester gadolinium exposure. Rational planning of healthcare policy and interventional measures are required to tackle CVD in pregnant women. However, several gaps exist in our knowledge, making it difficult to plan interventional strategies and base recommendations, particularly, in relation to the use of CMR in pregnancy. First, the indications for use of CMR in pregnancy have not been clearly delineated. Second, the impact of CMR on management of CVD in pregnancy is unclear. Therefore, our aims in this study were (i) to describe the indications for CMR in pregnancy; (ii) to assess the impact of CMR on management of CVD in pregnancy; and (iii) to make recommendations for optimal CMR approaches to cardiovascular imaging in pregnancy.
Methods

Study population
Modelled on the EuroCMR registry, 7 we included pregnant patients scanned consecutively in four centres in South Africa and the UK from 2008 till 2017: Groote Schuur Hospital (Cape Town, South Africa), John Radcliffe Hospital (Oxford, UK), The Heart Hospital and later Barts Heart Centre (London, UK), and Great Ormond Street Hospital (London, UK). Patient data were anonymized at the individual centres and no patient identifiable data left the individual centres.
Cardiovascular magnetic resonance
Patients were mainly in the second trimester at the time of imaging. Previous medical history and indications for CMR were reviewed. Imaging was carried out on 1.5 T MRI scanners. Coils used for imaging included a spine array posteriorly and a phased multi-channel flex array placed over the anterior chest. Patients were placed in the supine position and after 20 weeks' gestation, a wedge was placed under the right hip to minimize aorto-caval compression. All images were acquired using electrocardiographic vector gating (VCG) and with breath-holding. The shortest protocols with the lowest gradients were applied and MRI sequences limited to answer the clinical question. Acquisitions were kept at normal operating mode with as low a specific absorption rate (SAR) as possible. The CMR imaging protocol comprised balanced steady state free precession (bSSFP) localizers in three orthogonal planes, anatomical imaging with Half-Fourier acquisition single shot turbo spin echo (HASTE) in different orthogonal planes, long-and short-axis bSSFP retrospectively gated breath-held cines for the visual assessment of ventricular function. Short-axis images were acquired for accurate analysis of ventricular function, size, and mass. Phase contrast velocity-encoded mapping was added for the haemodynamic evaluation of flow and peak velocity in patients with valvular disease, congenital heart lesions, or aortic disease. At least two observers with a minimum of 5 years of CMR experience analysed the CMR images offline.
Descriptive statistics were applied and MS excel was used for calculations.
Results
Between the four centres included, 83 patients (age range 16-44 years, median age 27) successfully underwent CMR whilst pregnant, with good image quality obtained. All women were scanned in supine position with wedges after 20 weeks' gestation to avoid cava compression, none in the left lateral position. No CMR related complications were observed. All scans were diagnostic with sufficient image quality.
Indications for CMR
The most frequent indication for CMR was assessment for vascular or congenital heart disease (48%), followed by myocarditis or cardiomyopathy (43%)-see Table 1 . In 83% of the vascular/congenital cohort, the diagnosis was previously known and CMR was used for follow-up. An example is shown in Figures 1 and 2 . In the South African cohort, myocarditis/cardiomyopathy was the most common reason for CMR in 53% of patients followed by vascular or congenital indications in 35% of patients. In the UK cohort, CMR referrals were dominated by vascular and congenital indications (52%), followed by myocarditis or cardiomyopathy in 43% of scans.
Use of gadolinium in pregnancy
Gadolinium contrast was administered in 16 out of 83 studies (19%). The indications for use of contrast were for evaluation for suspected ischaemia/coronary disease (2/16), myocarditis/cardiomyopathy (12/ 16), see Figure 3 , and pericardial disease (2/16). No contrast was used for assessment of vascular or congenital pathology.
Impact of CMR on management of CVD in pregnancy
In 50% of the scans where contrast was used, management changed because of the scan. Overall, a new, previously unsuspected diagnosis was found in 11 (9%), and management was altered consequent to the scan in 42 patients (35%) ( Table 1) . In two patients, the findings of the scan resulted in termination of pregnancy. One of these had a known diagnosis of pulmonary atresia with major aorto-pulmonary collateral arteries, and the severity of her disease was considered prohibitive with regard to continuation of pregnancy. The other patient presented at 9/40 gestation with dilated cardiomyopathy (DCM) and poor left ventricular (LV) function. It is not known whether this pregnancy was planned, or if indeed the patient received pre-conception counselling. In 19 patients (23%), a suspected diagnosis was refuted and the patients were able to continue their pregnancy normally. Most of these patients (10/19) had suspected aortic pathology excluded, another four ventricular impairment suspected on echo, four had structural cardiac abnormalities excluded, and one suspected ischaemia. The impact of the scan on management for the patients receiving contrast is outlined in In this study, CMR yielded important diagnostic information effecting change of management in more than a third of patients studied. In other cases, excluding a suspected diagnosis allowed the pregnant women to be treated as normal, thereby 'de-medicalizing' their antenatal and peripartum care. The main indications for CMR in pregnancy include vascular or congenital heart disease, myocarditis or cardiomyopathy, and pericardial disease, though there are geographic differences. The results have implications for the management of CVD in pregnancy, and suggest that CMR should be used in pregnancy where it can potentially improve the care of the patient; and that the use of contrast CMR studies for compelling indications has a high likelihood of confirming or changing the diagnosis and thus altering the management of the patient. The appropriate use of CMR in pregnancy may potentially reduce the effect of CVD on maternal morbidity and mortality. Although echocardiography remains the imaging modality of choice in pregnant women, 13, 14 acoustic windows often deteriorate with advancing pregnancy making optimal imaging difficult. In addition, extracardiac pathology such as aortopathy or other congenital pathology cannot always be monitored reliably with echocardiography alone.
In our study, in many instances where CMR did not identify a new diagnosis, the scans were used for monitoring pre-existing cardiovascular conditions where echo alone was insufficient. Patients with aortic disease, for example, were monitored during pregnancy as per current guidelines. 15 As a result, many women were able to continue their pregnancies who otherwise may have been advised to terminate for medical reasons. In this study, 19% of pregnant patients were administered gadolinium contrast. This is in contrast to the findings of the EuroCMR registry, 7 where 88% of patients received contrast. However, this striking difference is not surprizing in the setting of a pregnant population where great care is taken to limit exposure of the foetus to contrast where possible. In some cases, however, the use of contrast is unavoidable and necessary for a complete assessment, especially in cases where the scan is undertaken for new or previously undiagnosed disease. This is particularly true for CMR studies for evaluation of suspected myocardial disease. According to current guidance, administration of contrast to pregnant mothers is permissible if the benefits of giving outweigh the risk to the foetus and where the result is important for the health of the mother. 16, 17 The observation that the change of management rate in this cohort receiving gadolinium was higher than in the noncontrast cohort provides compelling evidence that in selected cases the administration of gadolinium contrast is necessary and beneficial. However, it is worth considering new evidence that gadolinium is deposited in the brain of humans after repeated administration. Ray et al. 8 report that foetal gadolinium exposure was associated with increased risk of stillbirth and neonatal death as well as an increased risk of rheumatological, inflammatory, or infiltrative skin conditions in the baby. On the other hand, significant maternal illness and haemodynamic compromise carries immediate high risk for the foetus. Therefore, the benefits of performing contrast-CMR may outweigh these potential foetal risks, although it seems prudent to limit foetal (and maternal) gadolinium contrast exposure to a minimum without compromising patient care. 18 The two most common indications for CMR were similar (vascular or congenital and myocarditis or cardiomyopathy), making up 92% of the UK and 88% of the South African patients. In the South African cohort, the higher proportion of patients referred for heart muscle disease assessment could reflect sub-Saharan African demographics where heart failure occurs at younger average age compared with high-income countries and where cardiomyopathy and hypertensive heart disease are the commonest causes of heart failure. [18] [19] [20] [21] The higher number of referrals for congenital and vascular indications in the UK cohort, on the other hand, could indicate the growing prevalence of patients with congenital heart disease or connective tissue diseases who reach childbearing age. 22 In a study of 34 women, CMR was used to develop reference values for cardiac indices during normal pregnancy and the post-partum state. 23 Small studies have evaluated the role of CMR in the assessment of aortic disease 24, 25 and congenital heart disease in pregnancy. 26, 27 Similarly, small studies have assessed the role of CMR in peripartum and DCM [28] [29] [30] [31] [32] and in myocarditis and infiltrating cardiomyopathy 33 during pregnancy and the puerperium. These studies have reported on a common finding of a poor prognosis in these myocardial disorders when focal myocardial fibrosis indicated by late gadolinium enhancement (LGE) is present. In this cross-sectional analysis of patients included into a registry of CMR examination in pregnancy, there has been no follow-up to assess the impact of LGE on outcomes in pregnancy or the post-partum period. Based on the initial observations and practice in this registry, we make recommendations on an optimal approach to CMR in practice-see Table 3 .
Once clinical need is established, informed consent should be obtained taking into account the patient's pregnant state. Reassurance should be given that to-date no adverse effects on the foetus from MRI have been described. The patient should be positioned in the scanner comfortably and safely as described in Table 3 , and ideally standard operating procedures for scanning pregnant women should be in place and followed. SAR, magnetic field strength and acoustic noise should be reduced to a minimum, and the necessity of contrast administration should be decided and discussed with the patient in advance. The scan duration should be kept to a minimum, and the results of the scan should be interpreted by an experienced reporter who has sound knowledge of cardiovascular pathophysiology. Vital parameters may need to be checked before and/or after the scan, and scan results communicated clearly and without delay to the referring team.
Study limitations
This study had several limitations. First, it has all the disadvantages inherent in a retrospective design. Second, the small sample size is a noteworthy limitation. Third, as with the nature of observational registries, there is significant clinical heterogeneity in the patients included. Fourth, the registry includes patients from high-, middle-, and low-income regions with marked geographic and economic heterogeneity. Fifth, the exclusion of patients with pacemakers and defibrillators, who are often deemed unsuitable for CMR, may have inadvertently excluded cases of severe CVD. However, this is likely to change in the next few years with evidence emerging that patients with non-magnetic resonance conditional pacemakers can be scanned. Sixth, there is no long-term follow-up of patients and their babies to assess outcomes longitudinally as this was beyond the scope of the study. Clinical follow-up post-partum and onwards was remote from the scanning centre, precluding access to accurate longterm outcome data in the majority of patients. This study specifically addresses immediate procedural outcomes from the CMR centre point of view. Finally, patients included in this registry are from tertiary centres, which may limit the generalizability of the findings. Given the complexity of the patients included, it is unlikely that these patients may have received care in lower healthcare settings. However, despite these limitations, we have achieved our goal of describing the indications for CMR and assessing the impact of CMR on managing CVD in pregnancy. Furthermore, we also provide recommendations for CMR in pregnancy.
Conclusions
In this registry, and the largest observational study of CMR in pregnancy, 83 women underwent CMR during pregnancy without immediate complications. All scans were diagnostic and change in management occurred in over a third of patients. Contrast was used where necessary, in line with current guidance. The indications for CMR in pregnancy were similar in the UK and South African cohorts. The findings from our study suggest that CMR should be considered in pregnancy where there is a high likelihood that the results may improve patient care, and that the use of contrast for compelling indications, in particular assessment of intrinsic myocardial disease, can alter patient management. We conclude that CMR should be offered to pregnant women where indicated, including the responsible administration of contrast in line with current guidelines; and that appropriate use of CMR in pregnancy may potentially reduce the effect of CVD on maternal morbidity and mortality.
